16/10/2026
āϏāĻā§āϤāύ āĻĨāĻžāĻā§āύ, āĻā§āϝāĻžāύā§āϏāĻžāϰ āĻŽā§āĻā§āϤ āĻā§āĻŦāύ āĻāĻžāĻāĻžāύ:
āĻā§āϝāĻžāύā§āϏāĻžāϰ āϏā§āĻā§āϰāĻŋāύāĻŋāĻ: āĻŦā§āϏ āĻ āϞāĻŋāĻā§āĻāĻāĻŋāϤā§āϤāĻŋāĻ āĻĒā§āϰāĻā§āĻāϞāĨ¤
āĻā§āϝāĻžāύā§āϏāĻžāϰ āϏā§āĻā§āϰāĻŋāύāĻŋāĻā§ā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻšāϞ⧠āϞāĻā§āώāĻŖ āĻĻā§āĻāĻž āĻĻā§āĻā§āĻžāϰ āĻāĻā§āĻ āĻā§āϝāĻžāύā§āϏāĻžāϰ āĻ
āĻĨāĻŦāĻž precancerous lesion āĻļāύāĻžāĻā§āϤ āĻāϰāĻžāĨ¤ āϤāĻŦā§ āϏāĻŦ āĻā§āϝāĻžāύā§āϏāĻžāϰā§āϰ āĻāύā§āϝ routine screening-āĻāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻāĨ¤ āϤāĻžāĻ āĻ
āĻĒā§āϰā§ā§āĻāύā§ā§ CT/PET scan, tumour marker āĻŦāĻž whole-body screening āύāĻž āĻāϰ⧠evidence-based screening āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
ā§§. āύāĻžāϰā§āĻĻā§āϰ āϏā§āĻā§āϰāĻŋāύāĻŋāĻ-- Cervical Cancer...
⧍⧧â⧍⧝ āĻŦāĻāϰ
Pap smear/cervical cytology-āĻĒā§āϰāϤāĻŋ ā§Š āĻŦāĻāϰ āĻ
āύā§āϤāϰ āĻ
āύā§āϤāϰāĨ¤
ā§Šā§Ļâā§Ŧā§Ģ āĻŦāĻāϰ---
Primary high-risk HPV test-āĻĒā§āϰāϤāĻŋ ā§Ģ āĻŦāĻāϰ
āĻ
āĻĨāĻŦāĻž Pap smear āĻĒā§āϰāϤāĻŋ ā§Š āĻŦāĻāϰ āĻ
āύā§āϤāϰ āĻ
āύā§āϤāϰāĨ¤ āĻ
āĻĨāĻŦāĻž HPV + Pap co-test āĻĒā§āϰāϤāĻŋ ā§Ģ āĻŦāĻāϰ
ā§Ēā§Ļâā§ā§Ē āĻŦāĻāϰ---
Mammography- āĻĒā§āϰāϤāĻŋ ⧍ āĻŦāĻāϰ
âĨā§ā§Ģ āĻŦāĻāϰ- Mammography..
⧍āĨ¤ Breast cancer-āĻāϰ average-risk āύāĻžāϰā§āĻĻā§āϰ āĻāύā§āϝ āĻŦāϰā§āϤāĻŽāĻžāύ USPSTF recommendation āĻšāϞ⧠ā§Ēā§Ļâā§ā§Ē āĻŦāĻāϰ āĻŦā§āϏ⧠āĻĒā§āϰāϤāĻŋ ⧍ āĻŦāĻāϰ mammographyāĨ¤
āĻŦāĻŋāĻļā§āώ āĻĻā§āϰāώā§āĻāĻŦā§āϝ : BRCA1/BRCA2 mutation, strong family history, āĻĒā§āϰā§āĻŦā§ chest irradiation, previous breast cancer āĻŦāĻž high-risk breast lesion āĻĨāĻžāĻāϞ⧠āĻāĻ āϏāĻžāϧāĻžāϰāĻŖ protocol āĻĒā§āϰāϝā§āĻā§āϝ āύā§āĨ¤ āĻāĻĻā§āϰ āĻāύā§āϝ āĻ
āύā§āĻ āĻāĻā§ āĻĨā§āĻā§ MRI + mammography āĻāĻŋāϤā§āϤāĻŋāĻ high-risk surveillance āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
ā§ŠāĨ¤ āĻĒā§āϰā§āώāĻĻā§āϰ āϏā§āĻā§āϰāĻŋāύāĻŋāĻ---
Prostate cancer ----
ā§Ēā§Ļâā§Ģā§Ē āĻŦāĻāϰ: āϏāĻžāϧāĻžāϰāĻŖāϤ strong family history/āĻŦāĻŋāĻļā§āώ high-risk population āĻšāϞ⧠āĻāĻā§āĻ āϏā§āĻā§āϰā§āύāĻŋāĻ- āĻāϰāĻž āϝāĻžā§āĨ¤
ā§Ģā§Ģâā§Ŧ⧝ āĻŦāĻāϰ: PSA test.. āĻĒā§āϰāϤāĻŋ ⧍ āĻŦāĻāϰ āĻ
āύā§āϤāϰ āĻ
āύā§āϤāϰāĨ¤
âĨā§ā§Ļ āĻŦāĻāϰ: routine PSA screening āϏāĻžāϧāĻžāϰāĻŖāϤ āϏā§āĻĒāĻžāϰāĻŋāĻļ āĻāϰāĻž āĻšā§ āύāĻžāĨ¤āĨ¤
ā§ĒāĨ¤ āύāĻžāϰ⧠āĻ āĻĒā§āϰā§āώâāĻāĻā§ā§āϰ āĻāύā§āϝ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϏā§āĻā§āϰāĻŋāύāĻŋāĻ
Colorectal cancer Screening -----
ā§Ēā§Ģâā§ā§Ģ āĻŦāĻāϰ: average-risk āĻŦā§āϝāĻā§āϤāĻŋāĻĻā§āϰ āύāĻŋā§āĻŽāĻŋāϤ colorectal cancer screening āĻāϰāĻž āĻāĻāĻŋā§āĨ¤
āĻŦāĻŋāĻāϞā§āĻĒāĻā§āϞ⧠āĻšāϞā§: FIT: āĻĒā§āϰāϤāĻŋ āĻŦāĻāϰ
Stool DNA-FIT: āĻĒā§āϰāϤāĻŋ ā§§âā§Š āĻŦāĻāϰ
Colonoscopy: āĻĒā§āϰāϤāĻŋ ā§§ā§Ļ āĻŦāĻāϰ
CT colonography: āĻĒā§āϰāϤāĻŋ ā§Ģ āĻŦāĻāϰāĨ¤āĨ¤ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻŦāĻŋāώ⧠āĻšāϞā§âFIT positive āĻšāϞ⧠colonoscopy āĻāϰāϤ⧠āĻšāĻŦā§;
ā§ā§Ŧâā§Žā§Ģ āĻŦāĻāϰ: āϏā§āĻŦāĻžāϏā§āĻĨā§āϝ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰ⧠selective screeningāĨ¤
ā§ĢāĨ¤ āĻĢā§āϏāĻĢā§āϏā§āϰ āĻā§āϝāĻžāύā§āϏāĻžāϰ----
āĻāĻāĻžāύ⧠āĻŦā§āϏ āĻāĻŦāĻ āϧā§āĻŽāĻĒāĻžāύā§āϰ history āϏāĻŦāĻā§ā§ā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
āϏāĻžāϧāĻžāϰāĻŖāĻāĻžāĻŦā§:
ā§Ģā§Ļâā§Žā§Ļ āĻŦāĻāϰ āĻŦā§āϏā§, āϝāĻžāĻĻā§āϰ āϧā§āĻŽāĻĒāĻžāύā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻā§ āĻāĻŦāĻ āĻŦāϰā§āϤāĻŽāĻžāύ⧠āϧā§āĻŽāĻĒāĻžāύ āĻāϰā§āύ āĻ
āĻĨāĻŦāĻž āϏāĻžāĻŽā§āĻĒā§āϰāϤāĻŋāĻ āϏāĻŽā§ā§ āĻā§ā§ā§āĻā§āύâāϤāĻžāĻĻā§āϰ āĻāύā§āϝ annual low-dose CT (LDCT) āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻšā§āĨ¤
***āĻāĻāĻāĻž āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻŦāĻŋāώ⧠āĻšāĻā§āĻā§-- âāĻŦā§āϏâ āĻāĻāĻŽāĻžāϤā§āϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤā§āϰ āĻāĻŋāϤā§āϤāĻŋ āύā§āĨ¤ Life expectancy, Family history, functional status, previous screening āĻāĻŦāĻ āϰā§āĻā§āϰ preference āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰ⧠āϏā§āĻā§āϰā§āύāĻŋāĻ- āĻļā§āϰā§, āĻāĻžāϞāĻŋā§ā§ āϝāĻžāĻā§āĻž āĻŦāĻž āĻŦāύā§āϧ āĻāϰāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻā§āĻž āĻāĻāĻŋāϤāĨ¤***